SCHEMBL1700871

SCHEMBL1700871

Cc1cccc(NC(c2ccccc2O)c2ccc3cccnc3c2O)n1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 7/20 0.76
MAPT P10636 8/20 0.68
TP53 P04637 7/20 0.68
SMN1; SMN2 Q16637 3/20 0.68
P4HB P07237 5/20 0.67
LMNA P02545 2/20 0.63
KDM4E B2RXH2 1/20 0.62
NPC1 O15118 1/20 0.62
POLB P06746 1/20 0.62
RAB9A P51151 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
USP2 O75604 1/20 0.61
THRB P10828 1/20 0.61
JMJD7 P0C870 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
HIF1A Q16665 1/20 0.58
HSD17B10 Q99714 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18131609 1.00 MDM2 (0.76) MDM2MAPTTP53SMN1; SMN2P4HB
SCHEMBL18131661 1.00 MDM2 (0.76) MDM2MAPTTP53SMN1; SMN2P4HB
SCHEMBL15783093 0.89 MAPT (0.80) MDM2MAPTTP53SMN1; SMN2P4HB
SCHEMBL9965620 0.89 MDM2 (0.86) MDM2MAPTTP53SMN1; SMN2P4HB
SCHEMBL9965628 0.88 TP53 (0.77) MDM2MAPTTP53SMN1; SMN2P4HB
SCHEMBL18197735 0.88 TP53 (0.79) MDM2MAPTTP53SMN1; SMN2P4HB
SCHEMBL15783201 0.87 P4HB (0.81) MDM2MAPTTP53SMN1; SMN2P4HB
SCHEMBL1700855 0.87 TP53 (0.79) MDM2MAPTTP53SMN1; SMN2P4HB
SCHEMBL9965573 0.86 MDM2 (1.00) MDM2MAPTTP53SMN1; SMN2P4HB
SCHEMBL18131665 0.86 MDM2 (0.74) MDM2MAPTTP53SMN1; SMN2P4HB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131096-A1 8-HYDROXY-QUINOLINE DERIVATIVES UBICHEM KUTATO KORLATOLT FELELOSSEGU TARSASAG (HU) 2013-05-23 US claimed
EP-2566849-A1 8-HYDROXY-QUINOLINE DERIVATIVES "Avidin" Kutató, Fejleszt És Kereskedelmi Korlatolt Felelossegu Tarsasag (HU) 2013-03-13 EP claimed
WO-2011148208-A1 8-HYDROXY-QUINOLINE DERIVATIVES "AVIDIN" KUTATÓ, FEJLESZTŐ ÉS KERESKEDELMI KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG (HU) 2011-12-01 WO claimed
US-20190330188-A1 ENANTIOMERS OF 8-HYDROXYQUINOLINE DERIVATIVES AND THE SYNTHESIS THEREOF AVIDIN CO. LTD (HU) 2019-10-31 US disclosed
EP-2566849-B1 8-HYDROXY-QUINOLINE DERIVATIVES AVIDIN KUTATO FEJLESZTOE ES KERESKEDELMI KORLATOLT FELELOESSEGUE TARSASAG (HU) 2019-09-18 EP disclosed
EP-2566849-B1 8-HYDROXY-QUINOLINE DERIVATIVES AVIDIN KUTATO FEJLESZTOE ES KERESKEDELMI KORLATOLT FELELOESSEGUE TARSASAG (HU) 2019-09-18 EP disclosed
US-10287265-B2 Enantiomers of 8-hydroxyquinoline derivatives and the synthesis thereof AVIDIN CO. LTD. (HU) 2019-05-14 US disclosed
US-8871937-B2 8-hydroxy-quinoline derivatives “AVIDIN” Kutato, Fejleszto es Kereskedelmi Korlatolt Felelossegu Tarsasag (HU) 2014-10-28 US disclosed
US-8871937-B2 8-hydroxy-quinoline derivatives “AVIDIN” Kutato, Fejleszto es Kereskedelmi Korlatolt Felelossegu Tarsasag (HU) 2014-10-28 US disclosed
US-8871937-B2 8-hydroxy-quinoline derivatives “AVIDIN” Kutato, Fejleszto es Kereskedelmi Korlatolt Felelossegu Tarsasag (HU) 2014-10-28 US disclosed
US-20130131096-A1 8-HYDROXY-QUINOLINE DERIVATIVES UBICHEM KUTATO KORLATOLT FELELOSSEGU TARSASAG (HU) 2013-05-23 US disclosed
US-20130131096-A1 8-HYDROXY-QUINOLINE DERIVATIVES UBICHEM KUTATO KORLATOLT FELELOSSEGU TARSASAG (HU) 2013-05-23 US disclosed
US-20130131096-A1 8-HYDROXY-QUINOLINE DERIVATIVES UBICHEM KUTATO KORLATOLT FELELOSSEGU TARSASAG (HU) 2013-05-23 US disclosed
WO-2011148208-A1 8-HYDROXY-QUINOLINE DERIVATIVES "AVIDIN" KUTATÓ, FEJLESZTŐ ÉS KERESKEDELMI KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG (HU) 2011-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10287265-B2 Enantiomers of 8-hydroxyquinoline derivatives and the synthesis thereof TPH1, HTR5A, TPH2 MDM2 3814/4885MAPT 3429/4885TP53 4452/4885
US-20190330188-A1 ENANTIOMERS OF 8-HYDROXYQUINOLINE DERIVATIVES AND THE SYNTHESIS THEREOF TPH1, TPH2, HTR5A MDM2 2226/4885MAPT 2690/4885TP53 3980/4885
US-20130131096-A1 8-HYDROXY-QUINOLINE DERIVATIVES CYP2C8, NQO1, KEAP1 MDM2 2015/4885MAPT 2319/4885TP53 4173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.